Beginning of clinical treatment using the 1.5 Tesla MR-Linac system in Japan: a narrative review.

Autor:	Takahashi N; Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan., Tanaka S; Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan., Umezawa R; Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan., Yamamoto T; Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan., Suzuki Y; Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan., Kishida K; Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan., Omata S; Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan., Arai K; Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan., Katsuta Y; Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan., Kadoya N; Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan., Jingu K; Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Jazyk:	angličtina
Zdroj:	Translational cancer research [Transl Cancer Res] 2024 Feb 29; Vol. 13 (2), pp. 1131-1138. Date of Electronic Publication: 2024 Feb 28.
DOI:	10.21037/tcr-23-1649
Abstrakt:	Background and Objective: In the field of radiation therapy, image-guided radiotherapy (IGRT) technology has been gradually improving and highly accurate radiation treatment has been possible. Research on IGRT using 1.5 Tesla magnetic resonance imaging (MRI) began in 1999, and a radiation therapy device called 1.5 Tesla magnetic resonance linear accelerator (MR-Linac), which combines a linear accelerator with 1.5 Tesla MRI, was developed in Europe. The aim of this review is to present an overview of 1.5 Tesla MR-Linac with a review of the literature and our experience. Methods: Reports related to 1.5 Tesla MR-Linac were searched for in PubMed and are discussed in relation to our experience. Key Content and Findings: The 1.5 Tesla MR-Linac enables IGRT using 1.5 Tesla MRI, further enhancing the precision of radiation therapy. Position verification by cone-beam computed tomography (CBCT) is performed in many institutions, but soft tissue contrast is often unclear in CBCT images of the abdomen and mediastinal organs. Since the 1.5 Tesla MR-Linac allows position verification using MRI, position verification can be performed using clear MRI even in regions where CBCT is unclear. With the 1.5 Tesla MR-Linac, it is possible to perform online adaptive radiotherapy (ART) using 1.5 Tesla MRI. Online ART is a method in which images are acquired while the patient is on the treatment table. The method is based on the current condition of the organs in the body on that day and an optimal treatment field is recreated. Additionally, it allows monitoring of tumor motion using cine images obtained by 1.5 Tesla MRI during the delivery of X-ray radiation. A previous report showed that patients with prostate cancer who received radiotherapy by MR-Linac had fewer side effects than those in patients who received conventional CBCT radiation therapy. Conclusions: The 1.5 Tesla MR-Linac obtained CE-mark certification in Europe in August 2018 and it has been used for clinical treatment. In Japan, clinical treatment using this device started in 2021. By using 1.5 Tesla MR-Linac, patients can be provided with higher precision radiotherapy. In this review, we provide an overview of 1.5 Tesla MR-Linac. Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1649/coif). N.T. serves as an unpaid editorial board member of Translational Cancer Research from February 2022 to January 2024. K.J. reports grants from Elekta, K.K. The other authors have no conflicts of interest to declare. (2024 Translational Cancer Research. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu